Desmopressin acetate, commercially known as DDAVP, is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), serving as a critical therapeutic agent for multiple endocrine and hematological disorders. With a global market valued at approximately USD 121.58 million in 2024​ and projected to grow at a 4.50% CAGR, this peptide medication represents a specialized yet essential segment of the global pharmaceutical supply chain . This comprehensive guide analyzes the global procurement landscape, identifying key buyer categories, regional trade patterns, and strategic insights for stakeholders navigating the desmopressin acetate supply chain. 1. Market Overview: Therapeutic Applications and Global Demand Drivers Desmopressin acetate addresses several critical medical conditions, creating diverse…